Meeting
2022 ASCO Annual Meeting
Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.
Authors
Benjamin Besse
Gustave Roussy Institute, Villejuif, France
Benjamin Besse , Rosario Garcia Campelo , Manuel Cobo-Dols , Elisabeth Anne Quoix , Anne Madroszyk , Enriqueta Felip , Federico Cappuzzo , Fabrice Denis , Werner Hilgers , Giampiero Romano , Didier Debieuvre , Domenico Galetta , Editta Baldini , Santiago Viteri Ramirez , Minh Duc Phan , Wolfgang Schuette , Alona Zer , Berangere Vasseur , Rafal Dziadziuszko , Giuseppe Giaccone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02654587
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9094)
DOI
10.1200/JCO.2022.40.16_suppl.9094
Abstract #
9094
Poster Bd #
81
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors.
First Author: Marina Chiara Garassino
Poster
2019 ASCO Annual Meeting
ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.
First Author: Enriqueta Felip
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2019 ASCO Annual Meeting
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
First Author: Lecia V. Sequist